Vivos Therapeutics (VVOS) Total Non-Current Liabilities (2022 - 2026)

Vivos Therapeutics (VVOS) has reported Total Non-Current Liabilities for 4 consecutive years, with $27.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 35.22% year-over-year to $27.2 million in Q2 2026; TTM through Jun 2026 was $27.2 million, a 35.22% increase from a year earlier, with the FY2025 full-year figure at $25.4 million, changed N/A from the prior year.
• Total Non-Current Liabilities was $27.2 million for Q2 2026 at Vivos Therapeutics, up from $25.0 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $27.2 million in Q2 2026 and troughed at $8.4 million in Q1 2022.
• A 4-year average of $17.3 million and a median of $20.1 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities advanced 4.25% in 2023 and surged 35.22% in 2026, its largest moves.
• Over 4 years, Total Non-Current Liabilities stood at $8.4 million in 2022, then climbed by 15.26% to $9.7 million in 2023, then soared by 161.88% to $25.4 million in 2025, then rose by 7.0% to $27.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $27.2 million (Q2 2026), $25.0 million (Q1 2026), and $25.4 million (Q4 2025), per Business Quant data.